Genmab A/S Release: New Preliminary Efficacy Data for Daratumumab Presented at American Society of Hematology
Published: Dec 10, 2012
Copenhagen, Denmark; December 9, 2012 – Genmab A/S (OMX: GEN) announced today new preliminary safety and efficacy data from the Phase I/II clinical study of daratumumab (HuMax®-CD38) in multiple myeloma. Of the three patients treated at the highest (and final) dose level in the study (24 mg/kg of daratumumab), two achieved a partial response (PR) and one achieved a minimal response (MR). Altogether, 8 of 12 patients in the study who received daratumumab at a dose level of 4 mg/kg or higher achieved at least a MR.